DDInter1638 DDInter1819
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Foscarnet
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Altretamine
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Polatuzumab vedotin
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Altretamine
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Polatuzumab vedotin